Skip to content

Scientific poster: A human iPSC-based platform to screen therapeutics for ALS using specific and robust phenotypic assays covering disease relevant readouts.

Ncardia author image

By Ncardia Stem Cell Experts

To enable fast and confident selection of effective therapies for ALS we develop specific and robust phenotypic assays to study protein mis-localization and aggregation with human iPSC-derived in vitro models.

In this study, we show our iPSC-based platform with miniaturized assays using human iPSC-derived motor neurons to study the effect of new therapeutics in recognized ALS phenotypes:

• Mis-localization of TDP-43 to the cytoplasm
• Aggregation of TDP-43
• Reduction of STMN2 protein levels
• Mis-splicing of STMN2
• Altered electrophysiological properties
• Neurofilament-L secretion

Additionally, this ALS in vitro model was successfully transduced and, when treated with a gene therapy candidate, reduction of TDP-43 aggregation was detected. 

Using this platform you can validate your therapeutics, but more importantly, progress with the subset of therapeutics that offer higher confidence for clinical success. 

A human iPSC-platform for ALS therapeutics
als poster

Download the poster by filling the form below: